Acute myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
Intervention 1: Intervention group: Patients receive 1 mg colchicine tablet made by Modava Pharmaceutical Company as 1 mg at first and 1 mg one hour after Primary PCI. Intervention 2: Control group: P
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: A patient over 20 years of age with ST Elevated MI who is a candidate for Primary PCI and presented within less than 12 hours of the onset of pain
Exclusion criteria
Exclusion criteria: Cardiogenic shock or hemodynamic instability Known hypersensitivity to colchicine Patients with a history of chronic kidney and liver disease Thrombocytopenia or leukopenia Pregnant or lactating women Patients receiving CYP3A4 inhibitors Patients already taking colchicine Patients who have evidence of active or inflammatory infection Patients with a history of AF or MI Patients with a history of CABG MI patients in the field of stent thrombosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of interleukin 1B levels. Timepoint: 24 hours after intervention. Method of measurement: Elisa Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of recurrent myocardial infarction. Timepoint: On a daily basis from the start of the intervention. Method of measurement: Follow-up of symptoms of myocardial infarction. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Farasatinasab
Iran University of Medical Sciences
Outcome results
None listed